Recent advancements have focused on improving delivery methods and specificity:
1. Nanoparticle Delivery: Nanoparticles offer a promising delivery system for RNAi therapeutics. They can be engineered to enhance stability and target specific tissues, minimizing off-target effects. 2. CRISPR-Cas Systems: CRISPR technology is being integrated with RNAi to create more precise and effective gene-silencing tools. This combination allows for the precise targeting of genes implicated in cancer. 3. Clinical Trials: Several RNAi-based therapies are undergoing clinical trials, showing promising results in targeting specific cancer types like liver cancer and solid tumors.
